CN118647595A - R-氯胺酮盐及其使用方法 - Google Patents

R-氯胺酮盐及其使用方法 Download PDF

Info

Publication number
CN118647595A
CN118647595A CN202280081833.8A CN202280081833A CN118647595A CN 118647595 A CN118647595 A CN 118647595A CN 202280081833 A CN202280081833 A CN 202280081833A CN 118647595 A CN118647595 A CN 118647595A
Authority
CN
China
Prior art keywords
theta
degrees
ketamine
tartrate
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280081833.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·朱马
T·A·凯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perceptual Neuroscience Inc
Original Assignee
Perceptual Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perceptual Neuroscience Inc filed Critical Perceptual Neuroscience Inc
Publication of CN118647595A publication Critical patent/CN118647595A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202280081833.8A 2021-10-12 2022-10-12 R-氯胺酮盐及其使用方法 Pending CN118647595A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254878P 2021-10-12 2021-10-12
US63/254878 2021-10-12
PCT/US2022/046412 WO2023064363A1 (en) 2021-10-12 2022-10-12 R-ketamine salts and methods of use thereof

Publications (1)

Publication Number Publication Date
CN118647595A true CN118647595A (zh) 2024-09-13

Family

ID=84331621

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280081833.8A Pending CN118647595A (zh) 2021-10-12 2022-10-12 R-氯胺酮盐及其使用方法

Country Status (8)

Country Link
US (1) US20240336556A1 (cg-RX-API-DMAC10.html)
EP (1) EP4416126A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024539623A (cg-RX-API-DMAC10.html)
CN (1) CN118647595A (cg-RX-API-DMAC10.html)
CA (1) CA3234818A1 (cg-RX-API-DMAC10.html)
IL (1) IL312041A (cg-RX-API-DMAC10.html)
MX (1) MX2024004478A (cg-RX-API-DMAC10.html)
WO (1) WO2023064363A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1444041A2 (en) 2001-09-21 2004-08-11 Solvias AG Sealing system with flow channels
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
WO2019065900A1 (ja) 2017-09-27 2019-04-04 国立大学法人千葉大学 神経変性疾患あるいは認知機能障害の予防または治療剤としてのr-ケタミンおよびその誘導体
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
US20220110889A1 (en) 2018-12-27 2022-04-14 National University Corporation Chiba University R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
KR20220002905A (ko) * 2019-03-25 2022-01-07 더글라스 파머수티클스 리미티드 서방형 약학 제제
EP3968979B1 (en) * 2019-05-15 2026-07-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
GB201912505D0 (en) * 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation

Also Published As

Publication number Publication date
MX2024004478A (es) 2024-07-01
US20240336556A1 (en) 2024-10-10
CA3234818A1 (en) 2023-04-20
WO2023064363A9 (en) 2024-02-15
WO2023064363A1 (en) 2023-04-20
EP4416126A1 (en) 2024-08-21
IL312041A (en) 2024-06-01
JP2024539623A (ja) 2024-10-29

Similar Documents

Publication Publication Date Title
JP3779682B2 (ja) 5,8,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11),3,5,7,9−ペンタンの酒石酸塩及びその医薬組成物
JP7199739B2 (ja) Gabaaの正のアロステリックモジュレーターの塩及び結晶形態
WO2010117738A2 (en) Solid state forms of sitagliptin salts
JP2025511847A (ja) ラニフィブラノールの結晶形態
TW202302582A (zh) Lsd鹽晶體形式
CN106661015A (zh) 达沙替尼盐
EP3743405B1 (en) Crystalline siponimod fumaric acid and polymorphs thereof
CN103298825B (zh) 具有所限定粒径的纯的非多晶型的结晶胆汁酸的优化合成
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
WO2017160703A1 (en) Solid state forms of nilotinib salts
US20240336556A1 (en) R-ketamine salts and methods of use thereof
CN108349903B (zh) Ttp488加成盐及其晶型、制备方法及药物组合物
KR20100074303A (ko) O-데스메틸벤라팍신 푸마레이트의 결정형
CN111484489B (zh) 无定形的b-raf激酶二聚体抑制剂
JP2025524904A (ja) ダプロデュスタットおよびその共結晶を調整するための方法
EP2729460B1 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
WO2019019130A1 (zh) 含恩替诺特的化合物,其化合物晶型及其制备方法和药物组合物
CN115448895B (zh) 一种沃替西汀前药的晶型、其制备方法和应用
KR102513519B1 (ko) 신규한 에독사반 벤젠술폰산염 1 수화물의 제조방법
BRPI0707997A2 (pt) forma cristalizada i de besipiridina.hcl, processo para sua obtenção, uso desta e composição terapêutica
JP5156381B2 (ja) N−メチル−N−(3−{3−[2−チエニルカルボニル]−ピラゾール−[1,5−α]−ピリミジン−7−イル}フェニル)アセトアミドの水和物ならびにそれに関連するプロセスおよび方法
CN101115706A (zh) 制备普伐他汀钠的方法
CN100591685C (zh) 一种医药化合物的结晶形式
NZ620864B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
WO2011121452A2 (en) Crystal forms of o-desmethylvenlafaxine fumarate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination